## **Expanded View Figures**



## Figure EV1. Specificity of phospho-antibodies.

A HEK293 cells were transfected with LRRK2[G2091S] or LRRK2[S1292A, G2019S]. 24 h post-transfection, cells were treated in the presence (+) or absence (-) of the LRRK2 inhibitor MLi-2 (100 nM, 60 min) lysed and analyzed by immunoblotting with the indicated antibodies.

- B As in (A) except that the indicated HA-tagged Rab isoforms were co-expressed with LRRK2[Y1699C] in HEK293 cells to maximally phosphorylate these isoforms. Lysates were subjected to immunoblotting with an anti-Rab29 phospho Thr71 antibody.
- C Same as (B) except for immunoblotting with an anti-Rab10 phospho Thr73 antibody. No signal is detected upon treatment with MLi-2 or mutation of Rab29 or Rab10 phospho-residue to an alanine. WT, wild type.



## Figure EV2. Rab29 selectively activates LRRK2.

A, B HEK293 cells were transfected with the wild-type LRRK2 (A) or LRRK2[R1441G] (B) with either HA-empty vector (–) or the indicated HA-tagged Rab proteins. 24 h post-transfection, cells were lysed and analyzed by immunoblotting with the indicated antibodies. Blots were quantified by LiCor and presented as average ± SEM, and analyzed using one-way ANOVA with Dunnett's multiple comparison test comparing all groups to the HA-empty vector (–). For (A) WT LRRK2, there was a statistically significant difference between groups (*P* = 0.0135, one-way ANOVA, *F*(11, 12) = 3.911). <sup>ns</sup>*P* > 0.05, \*\**P* < 0.01 by one-way ANOVA with Dunnett's multiple comparison test comparing all groups to the HA-empty vector (–). For (A) WT LRRK2, there was a statistically significant difference between groups (*P* = 0.0135, one-way ANOVA, *F*(11, 12) = 3.911). <sup>ns</sup>*P* > 0.05, \*\**P* < 0.01 by one-way ANOVA with Dunnett's multiple comparison test with mean difference 95% confidence intervals of groups compared to HA-empty vector control: Rab1B – 356.9 to 332.6; Rab5B – 342.0 to 347.6; Rab7A – 332.4 to 357.2; Rab8A – 378.6 to 311.0; Rab8B – 346.7 to 342.9; Rab10 – 372.3 to 317.3; Rab12 – 499.8 to 189.8; Rab29 – 865.3 to -175.7; Rab32 – 372.7 to 316.8; Rab38 – 367.4 to 322.2; Rab39B – 346.5 to 343.1. For (B) LRRK2[R1441G], there was also a statistically significant difference between groups (*P* = 0.0007, one-way ANOVA, *F*(11, 12) = 7.642). <sup>ns</sup>*P* > 0.05, \*\*\**P* < 0.001 by one-way ANOVA with Dunnett's multiple comparison test with mean difference 95% confidence intervals of groups compared to HA-empty vector control: Rab1B – 366.5 to 411.2; Rab5B – 410.2 to 387.5; Rab7A – 377.0 to 420.7; Rab8A – 668.2 to 129.6; Rab8B – 517.5 to 280.3; Rab10 – 421.1 to 376.7; Rab12 – 503.2 to 294.6; Rab29 – 1,243 to -445.7; Rab32 – 433.5 to 364.3; Rab38 – 548.2 to 249.5; Rab39B – 390.4 to 407.4. Results were obtained in two separate experiments, each performed in duplicate.





## Figure EV3. Investigation of Rab29 mutations that potentially interrupt Rab29 binding to LRRK2.

- A Sequence alignment of the indicated Rab protein Switch II effector motifs. The MTR sequence that mediates interaction of Rab32 with the ankyrin domain of VARP is highlighted in a red box.
- B HEK293 cells were transfected with the indicated wild-type and mutant forms of LRRK2 with either HA-empty vector (–) or HA-tagged wild-type Rab29 (WT) or HA-tagged mutant Rab29[M73S,R75S]. 24 h post-transfection, cells were lysed and analyzed by immunoblotting with the indicated antibodies. WT is wild-type and KD corresponds to the kinase dead [D2017A] LRRK2 mutant. Similar results were obtained in two experiments.
- C HeLa cells expressing HA-tagged Rab29 WT or M73S R75S proteins, stained with mouse anti-HA antibody, and analyzed by immunofluorescence microscopy. Scale bars represent 10  $\mu$ m.